Enterocin 14 : in vitro, in situ and in vivo activity data
Djamel DIDER & Rozenn RAVALLEC
UMR-T BioEcoAgro INRAe 1158 – Université de Lille, France
Email (email@example.com) & (firstname.lastname@example.org)
Enterocin 14 (EntDD14) is a leaderless class IIb bacteriocin produced by Enterococcus faecalis 14, a strain isolated from meconium . Purification and characterization of this bacteriocin revealed that it comprises two complementary peptides EntDD14A (MGAIAKLVAKFGWPIVKKYYKQIMQFIGEGWAINKIIDWIKKHI) and EntDD14B (MGAIAKLVAKFGWPFIKKFYKQIMQFIGQGWTIDQIEKWLKRH) . Bacteriocin’s antimicrobial activity against a panel of Gram-positive and Gram-negative bacteria and microscopic fungi has been studied and the enterocin was active only against a group of genetically related Gram-positive bacteria [1 and new data]. However, this bacteriocin could be of interest for medical purposes due to its activity against potentially dangerous pathogens including Clostridium perfringens and Staphylococcus aureus  and its ability to enhance the activity of antibiotics such as erythromycin, kanamycin , and methicillin . To verify these results, we conducted in situ studies to establish the EntDD14 efficiency alone or in combination with methicillin in limiting Staphylococcus aureus adhesion to human cells Caco-2. EntDD14 has also been shown to reduce the synthesis of interleukins IL-6 and IL-8 . This activity was validated in vivo using the murine model "holoxenic NMRI-F". We analyzed the impact of the bacteriocin (EntDD14), alone or in combination with erythromycin, against a methicillin-resistant Staphylococcus aureus strain (MRSA) in a murine model infected with this strain. We observed that treatment of the group of mice infected with MRSA (108 cfu) and EntDD14 (165 mg/kg), or EntDD14 (165 mg/kg) combined with erythromycin (100 mg/kg) allowed (i) better histopathological protection of the liver, spleen, and colon, (ii) improved body weight recovery, and (iii) a more stable intestinal microbiota in comparison with untreated infected mice or mice treated only with the antibiotic .
- Al Atya AK, Drider-Hadiouche K, Ravallec R, Silvain A, Vachee A, Drider D (2015). Probiotic potential of Enterococcus faecalis strains isolated from meconium.Frontiers in Microbiology. 2;6:227. doi: 10.3389/fmicb.2015.00227. eCollection 2015.
- Caly DL, Chevalier M, Flahaut C, Cudennec B, Al Atya AK, Chataigné G, D'Inca R, Auclair E, Drider D (2017). The safe enterocin DD14 is a leaderless two-peptide bacteriocin with anti-Clostridium perfringens activity.International Journal of Antimicrobial Agents. 49:282-289. doi: 10.1016/j.ijantimicag.2016.11.016.
- Al Atya AK, Belguesmia Y, Chataigne G, Ravallec R, Vachée A, Szunerits S, Boukherroub R, Drider D (2016). Anti-MRSA Activities of Enterocins DD28 and DD93 and Evidences on Their Role in the Inhibition of Biofilm Formation.Frontiers in Microbiology. 31;7:817. doi: 10.3389/fmicb.2016.00817. eCollection 2016.
- Belguesmia Y, Spano G, Drider D. (2021). Potentiating effects of leaderless enterocin DD14 in combination with methicillin on clinical methicillin-resistant Staphylococcus aureus S1 strain.Microbiology Research. 252:126864. doi: 10.1016/j.micres.2021.126864.
- Teiar R, Pérez-Ramos A, Zgheib H, Cudennec B, Belguesmia Y, Drider D (2022). Anti-adhesion and Anti-inflammatory Potential of the Leaderless Class IIb Bacteriocin Enterocin DD14.Probiotics and Antimicrobial Proteins. 14(4):613-619. doi: 10.1007/s12602-022-09954-0.
- Bendjeddou K, Hamma-Faradji S, Meddour AA, Belguesmia Y, Cudennec B, Bendali F, Daube G, Taminiau B, Drider D. (2021). Gut microbiota, body weight and histopathological examinations in experimental infection by methicillin-resistant Staphylococcus aureus: antibiotic versus bacteriocin.Beneficial Microbes. 15;12(3):295-305. doi: 10.3920/BM2020.0155.